Differences between the PPMI and S4 cohorts included a longer disease duration for PD participants in the S4 dataset, a higher percentage of healthy controls in S4, and no identified LRRK2 or GBA pathogenic carriers in S4 (Table 1). This evidence concerns the gene LRRK2 and Parkinson disease.